Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Tanya Dorff, MD, elaborates on data investigating atezolizumab and cabozantinib in prostate cancer

Dr. Dorff, Associate Clinical Professor, City of Hope, shares perspective on data presented at ASCO GU20 investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

Tags: ASCO GU Conference CoverageFeaturedProstate

Published: 17 February 2020

Recent Videos

video

Michael Atkins, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCC patients

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, on appropriate patient types to receive a TKI in the treatment of ...

video

Michael Atkins, MD, discusses the 4 year follow up of Checkmate-214 investigating nivolumab + ipilimumab in 1st line renal cell carcinoma patients

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, on the results of the 4 year follow up of Checkmate-214 investigating ...

video

Tanya Dorff, MD, on the future of cellular immunotherapy versus checkpoint inhibition in mPC

Dr. Dorff, Associate Clinical Professor, City of Hope, shares thoughts on the future of cellular immunotherapy versus checkpoint inhibition in ...

video

Tanya Dorff, MD, shares thoughts of the optimal sequence of atezolizumab and sip-T in mCRPC

Dr. Dorff, Associate Clinical Professor, City of Hope, shares thoughts of the optimal sequence of atezolizumab and sip-T in metastatic ...

video

Oliver Sartor, MD, on the exciting recent outcomes investigating Lu-177–PSMA in patients with advanced prostate cancer

Dr. Sartor, Professor of Medicine and Urology, Tulane University School of Medicine, on the exciting recent outcomes investigating Lu-177–PSMA ...

video

Arlene Siefker-Radtke, MD, shares the role of selecting mutations vs amplification for urothelial cancer treatment

Dr. Siefker-Radtke, Professor, MD Anderson Cancer Center, shares the role of selecting mutations vs amplification for the treatment of urothelial ...

video

Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancer

Dr. Siefker-Radtke, Professor, MD Anderson Cancer Center, regarding the development of erdafitinib in bladder cancer

video

Robert Figlin, MD, shares exciting potential of current late-stage clinical studies in RCC patients

Dr. Figlin, Professor, Cedars Sinai Medical Center, shares exciting potential of current late-stage clinical studies in renal cell cancer patients ...

video

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line renal cell carcinoma patients

Dr. Figlin, Professor, Cedars Sinai Medical Center, on appropriate patient types to receive a TKI in the treatment of 1st ...

video

Lucia Nappi, MD, explains micro RNA usage to aid in the diagnosis and treatment of testicular cancer

Dr. Nappi, Senior Research Scientists, Vancouver Prostate Center, explains the use of micro RNA to aid in the diagnosis and ...

Related Videos

video-image

Oliver Sartor, MD, elaborates on presented data investigating atezolizumab and cabozantinib in mCRPC

video-image

Yung Lyou, MD, summarizes the EV103 study investigating enfortumab + pembrolizumab

video-image

Michael Atkins, MD, discusses the 4 year follow up of Checkmate-214 investigating nivolumab + ipilimumab in 1st line renal cell carcinoma patients

video-image

Bradley McGregor, MD, shares presented data investigating atezolizumab and cabozantinib in mCRPC

video-image

Michael Atkins, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCC patients

video-image

Landon Brown, MD, on using CTC to sub classify patients and identifying patients with biomarkers

video-image

David Quinn, MD, on how the measurement of CTC may or may not be changing the treatment of urothelial cancer

video-image

Lucia Nappi, MD, explains micro RNA usage to aid in the diagnosis and treatment of testicular cancer

video-image

Daniel Petrylak, MD, expresses the efficacy of infigratinib in FGFR3-altered mUC patients

video-image

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line renal cell carcinoma patients

video-image

Daniel Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in mCRPC

video-image

Robert Figlin, MD, shares exciting potential of current late-stage clinical studies in RCC patients

video-image

Daniel Petrylak, MD, explains the effect of second antigen spread in mCRPC patients

video-image

Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancer

video-image

Anis Hamid, MD, describes real world impact of immunotherapy when added to oral therapies for advanced prostate cancer

video-image

Arlene Siefker-Radtke, MD, shares the role of selecting mutations vs amplification for urothelial cancer treatment

video-image

Anis Hamid, describes how RNA profiling guides treatment decisions about chemotherapy for metastatic prostate cancer

video-image

Oliver Sartor, MD, on the exciting recent outcomes investigating Lu-177–PSMA in patients with advanced prostate cancer

video-image

Yung Lyou, MD, on the relationship between hyperphosphatemia and infigratinib efficacy in urothelial carcinoma

video-image

Tanya Dorff, MD, shares thoughts of the optimal sequence of atezolizumab and sip-T in mCRPC